NCT00624364View on ClinicalTrials.gov

Efficacy and Safety of Biphasic Insulin Aspart 30 With Metformin in Type 2 Diabetes

PHASE4CompletedINTERVENTIONAL
Enrollment

140

Participants

Timeline

Start Date

May 31, 2004

Primary Completion Date

May 31, 2005

Study Completion Date

May 31, 2005

Conditions
DiabetesDiabetes Mellitus, Type 2
Interventions
DRUG

biphasic insulin aspart

DRUG

metformin

Trial Locations (15)

1500

Novo Nordisk Investigational Site, Benoni

1827

Novo Nordisk Investigational Site, Johannesburg

1829

Novo Nordisk Investigational Site, Johannesburg

2001

Novo Nordisk Investigational Site, Johannesburg

3235

Novo Nordisk Investigational Site, Pietermaritzburg

3900

Novo Nordisk Investigational Site, Richards Bay

4001

Novo Nordisk Investigational Site, Durban

4091

Novo Nordisk Investigational Site, Durban

7708

Novo Nordisk Investigational Site, Cape Town

7800

Novo Nordisk Investigational Site, Cape Town

8301

Novo Nordisk Investigational Site, Kimberley

9301

Novo Nordisk Investigational Site, Bloemfontein

0116

Novo Nordisk Investigational Site, Pretoria

0250

Novo Nordisk Investigational Site, Brits

27 51

Novo Nordisk Investigational Site, Bloemfontein

Sponsors

Lead Sponsor

Novo Nordisk A/S
All Listed Sponsors
lead

Novo Nordisk A/S

INDUSTRY

NCT00624364 - Efficacy and Safety of Biphasic Insulin Aspart 30 With Metformin in Type 2 Diabetes | Biotech Hunter | Biotech Hunter